Prexige is a medicine containing the active ingredient(s) lumiracoxib. On this page you will find out more about Prexige, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: lumiracoxib
No information has been found for the selected product. Contact your pharmacist, healthcare professional, or phone healthdirect on 1800 022 222 if you require further help.
Found 0 results
Found 1 results
Single dose oral lumiracoxib (Prexige) for acute postoperative pain relief in adults | Cochrane
Postoperative pain is often poorly managed. Cyclooxygenase inhibitors (COX-2) pain relieving drugs were developed with the aim of reducing the gastrointestinal side effects of non-steroidal anti-inflammatory drugs (NSAIDs). Lumiracoxib 400 mg provided rapid, effective, and sustained relief of postoperative pain in four studies in dental and orthopaedic surgery. Of 366 participants treated with lumiracoxib 400 mg half experienced a high level of pain relief (at least 50% pain relief over a six hour period), compared with 8% given placebo. The duration of analgesia was relatively long at 9 hours, and fewer participants needed to use rescue medication with lumiracoxib than with placebo. Adverse event data was inconsistently reported, but no serious adverse events occurred in any patient taking lumiracoxib in these studies.
Read more on Cochrane (Australasian Centre) website